Faron Pharmaceuticals Oy (DI) (FARN) RNS Announcements

Add to Alert list
Date Time Source Announcement
30 Aug 2024 07:00 AM
RNS
Grant of options
27 Aug 2024 07:00 AM
RNS
FDA Grants Fast Track Designation for Bexmarilimab
27 Aug 2024 07:00 AM
RNS
Faron 2024 Half-Year Financial Results
20 Aug 2024 07:00 AM
RNS
Notice of Half-Year Financial Results
13 Aug 2024 07:00 AM
RNS
Traumakine Research Collaboration and DoD Grant
08 Aug 2024 07:00 AM
RNS
Appointment of Chief Financial Officer
07 Aug 2024 10:00 AM
RNS
Grant of options
06 Aug 2024 08:30 AM
RNS
Faron Appoints Dr. Petri Bono as new CMO
11 Jul 2024 07:00 AM
RNS
Faron Announces Positive FDA Feedback
25 Jun 2024 02:00 PM
RNS
Update on settlement
25 Jun 2024 10:30 AM
RNS
Holding(s) in Company - Replacement
24 Jun 2024 12:45 PM
RNS
Holding(s) in Company
24 Jun 2024 12:45 PM
RNS
Holding(s) in Company
24 Jun 2024 12:45 PM
RNS
Holding(s) in Company
24 Jun 2024 12:45 PM
RNS
Holding(s) in Company
20 Jun 2024 01:00 PM
RNS
New shares registered with Finnish Trade Register
20 Jun 2024 07:00 AM
RNS
Fully subscribed EUR 30.7 million share offering
05 Jun 2024 08:00 AM
RNS
Proposed REX Retail Offer
04 Jun 2024 07:00 AM
RNS
Faron commences a share offering
20 May 2024 07:00 AM
RNS
Initial positive data from Phase 2 of BEXMAB
17 May 2024 04:00 PM
RNS
Issuance of warrants
16 May 2024 07:05 AM
RNS
Founders named European Inventor Award finalists
13 May 2024 07:00 AM
RNS
Replacement – Board Change
30 Apr 2024 02:00 PM
RNS
Update on financial status
30 Apr 2024 01:00 PM
RNS
Board Change
16 Apr 2024 07:00 AM
RNS
Faron confirms plans under new leadership
15 Apr 2024 07:00 AM
RNS
Appointment of Chief Financial Officer
08 Apr 2024 07:10 AM
RNS
Approval of Warrant Terms and Conditions
08 Apr 2024 07:05 AM
RNS
Decisions of the Board of Directors
08 Apr 2024 07:00 AM
RNS
Appointment of Chief Executive Officer
05 Apr 2024 12:00 PM
RNS
Results of the Annual General Meeting
04 Apr 2024 07:00 AM
RNS
Announcement of Placing
28 Mar 2024 07:00 AM
RNS
Issue of Warrants to IPF Funding Update
26 Mar 2024 10:00 AM
RNS
Faron´s Annual Report 2023
18 Mar 2024 07:00 AM
RNS
Additional Positive Data from Phase 1 of BEXMAB
14 Mar 2024 07:00 AM
RNS
Faron to Host BEXMAB Webcast
13 Mar 2024 02:00 PM
RNS
Notice of Annual General Meeting 2024
13 Mar 2024 07:00 AM
RNS
Financial Statement January 1 to December 31 2023
04 Mar 2024 07:00 AM
RNS
Binding commitments for convertible loans
28 Feb 2024 04:00 PM
RNS
Replacement - Update to 2024 Financial Calendar
27 Feb 2024 06:00 PM
RNS
Update to Faron’s Financial Calendar for 2024
21 Feb 2024 02:00 PM
RNS
Continued Negotiations Regarding Events of Default
19 Feb 2024 10:30 AM
RNS
Events of Default
31 Jan 2024 07:00 AM
RNS
Further re: Exercise of options
25 Jan 2024 07:00 AM
RNS
BEXMAB Insights into Patient Profiles
19 Jan 2024 01:00 PM
RNS
Exercise of options - Issue of equity
09 Jan 2024 07:00 AM
RNS
First Patient Dosed in Ph 2 of the BEXMAB Trial
03 Jan 2024 07:00 AM
RNS
Presentation at J.P. Morgan Healthcare Conference
22 Dec 2023 07:00 AM
RNS
Faron’s Financial Calendar for 2024
11 Dec 2023 07:00 AM
RNS
Phase 1 BEXMAB data presented at ASH
UK 100

Latest directors dealings